18.80
-1.16(-5.81%)
Currency In USD
| Previous Close | 19.96 |
| Open | 21.29 |
| Day High | 21.44 |
| Day Low | 18.74 |
| 52-Week High | 45.37 |
| 52-Week Low | 13.22 |
| Volume | 1.01M |
| Average Volume | 837,675 |
| Market Cap | 1.08B |
| PE | -5.97 |
| EPS | -3.15 |
| Moving Average 50 Days | 19.42 |
| Moving Average 200 Days | 24.62 |
| Change | -1.16 |
If you invested $1000 in Structure Therapeutics Inc. (GPCR) since IPO date, it would be worth $723.08 as of August 20, 2025 at a share price of $18.8. Whereas If you bought $1000 worth of Structure Therapeutics Inc. (GPCR) shares 1 year ago, it would be worth $466.85 as of August 20, 2025 at a share price of $18.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
GlobeNewswire Inc.
Jun 20, 2025 11:30 PM GMT
SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming la
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
GlobeNewswire Inc.
Jan 30, 2025 1:30 PM GMT
SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
GlobeNewswire Inc.
Dec 17, 2024 9:01 PM GMT
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug can